The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Share
1
Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, IRCCS Istituto Auxologico Italiano, Milan, Italy. Electronic address: peter.schwartz@unipv.it.
2
Department of Biomedical Informatics, University of Arizona College of Medicine, Phoenix, Arizona; AZCERT, Inc., Oro Valley, Arizona.
1
Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, IRCCS Istituto Auxologico Italiano, Milan, Italy. Electronic address: peter.schwartz@unipv.it.
2
Department of Biomedical Informatics, University of Arizona College of Medicine, Phoenix, Arizona; AZCERT, Inc., Oro Valley, Arizona.
Drug-induced long QT syndrome (diLQTS) and congenital LQTS (cLQTS) share many features, and both syndromes can result in life-threatening torsades de pointes (TdP). Our understanding of their mechanistic and genetic similarities has led to their improved clinical management. However, our inability to prevent diLQTS has resulted in removal of many medicines from the market and from development. Genetic and clinical risk factors for diLQTS and TdP are well known and raise the possibility of TdP prevention. Clinical decision support systems (CDSS) can scan the patient's electronic health records for clinical risk factors predictive of diLQTS and warn when a drug that can cause TdP is prescribed. CDSS have reduced prescriptions of QT-prolonging drugs, but these relatively small changes lack the power to reduce TdP. The growing genetic evidence linking diLQTS to cLQTS suggests that prevention of TdP in the future may require inclusion of both genetic and clinical predictors into CDSS.
Sarganas G, et al.
Europace. 2014 Jan;16(1):101-8. doi: 10.1093/europace/eut214. Epub 2013 Jul 5.
Europace. 2014.
PMID:
23833046
McCauley MD, et al.
Clin Pharmacol Ther. 2016 Oct;100(4):324-6. doi: 10.1002/cpt.408. Epub 2016 Aug 1.
Clin Pharmacol Ther. 2016.
PMID:
27301674
Free PMC article.
Dilaveris PE.
Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):105-18. doi: 10.2174/1568016053544318.
Curr Med Chem Cardiovasc Hematol Agents. 2005.
PMID:
15853698
Review.
Lawrence CL, et al.
J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):46-59. doi: 10.1016/j.vascn.2005.04.011.
J Pharmacol Toxicol Methods. 2005.
PMID:
15975832
Review.
Weeke P, et al.
J Am Coll Cardiol. 2014 Apr 15;63(14):1430-7. doi: 10.1016/j.jacc.2014.01.031. Epub 2014 Feb 19.
J Am Coll Cardiol. 2014.
PMID:
24561134
Free PMC article.
Guo H, et al.
Eur J Clin Pharmacol. 2023 Jun;79(6):759-765. doi: 10.1007/s00228-023-03492-6. Epub 2023 Apr 11.
Eur J Clin Pharmacol. 2023.
PMID:
37039873
Schulze Westhoff M, et al.
Front Psychiatry. 2023 Mar 23;14:1157996. doi: 10.3389/fpsyt.2023.1157996. eCollection 2023.
Front Psychiatry. 2023.
PMID:
37032947
Free PMC article.
Rowe EJ, et al.
Front Cardiovasc Med. 2022 Dec 15;9:894623. doi: 10.3389/fcvm.2022.894623. eCollection 2022.
Front Cardiovasc Med. 2022.
PMID:
36588548
Free PMC article.
